Loading...
Proton-pump inhibitors (PPIs) do not produce predictable clinical responses in all patients with acid-related diseases; some of this variability likely is due to altered bioavailability because of variations in metabolic clearance. Omeprazole, lansoprazole, pantoprazole, and rabeprazole are metabolized predominately by cytochrome protein (CYP) 2C19 and to a lesser degree by CYP3A4. Recent reports of a CYP2C19 genetic polymorphism revealed considerable variation in expression among some ethnic groups and across the population. In contrast, CYP3A4 is subject to considerably less variable expression. In this randomized, crossover, parallel-group study, researchers evaluated the effects of CYP2C19 genotype on the bioavailability of rabeprazole …